Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180)

  • J Med Chem. 2007 Nov 29;50(24):5890-3. doi: 10.1021/jm7010595.
Jun Li  1 ,  Stephanie Y Chen ,  James J Li ,  Haixia Wang ,  Andres S Hernandez ,  Shiwei Tao ,  Christa M Musial ,  Fucheng Qu ,  Stephen Swartz ,  Sam T Chao ,  Neil Flynn ,  Brian J Murphy ,  Dorothy A Slusarchyk ,  Ramakrishna Seethala ,  Mujing Yan ,  Paul Sleph ,  Gary Grover ,  Mark A Smith ,  Blake Beehler ,  Leah Giupponi ,  Kenneth E Dickinson ,  Hongjian Zhang ,  William G Humphreys ,  Bharat P Patel ,  Mark Schwinden ,  Terry Stouch ,  Peter T W Cheng ,  Scott A Biller ,  William R Ewing ,  David Gordon ,  Jeffrey A Robl ,  Joseph A Tino
Affiliations
  • 1. Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5400, Princeton, NJ 08543, USA. [email protected]
PMID: 17973363 DOI: 10.1021/jm7010595
Abstract

A tetrazole-based peptidomimetic 2 (BMS-317180) was discovered as a human growth hormone secretagogue (GHS). Compound 2 is a potent, novel, orally effective GHS that shows an excellent safety profile in preclinical studies. The compound was advanced into clinical development.

Products